13 
difficult for a single individual to represent the breadth of industrial 
experience. He said it is also difficult for a single individual to represent 
industry as a whole as opposed to his own organization. 
In conclusion, Dr. Uaitz thanked the working group for the opportunity to 
participate in the dialogue. He said industry believes it benefits from 
continued communication with the Large-Scale Review Working Group; the working 
group has provided and, hopefully, will continue to provide a forum for discus- 
sion regarding large-scale uses of recombinant ENA technology. Industry has 
become substantially involved in biotechnology and its involvement is likely 
to increase as more is learned about use possibilities. For this reason, 
industry believes it is important for the Large-Scale Review Vtorking Group to 
continue to function as a committee and to focus on issues vhich may be unique 
to industrial or other large-scale uses. 
Dr . V.’aitz said that Schering-Plough Corporation welcomes the opportunity to be 
of assistance in refining the NIH Guidelines and the Large-Scale Physical 
Gontainment Recommendations. Through combined efforts greater confidence 
that the guidelines will further this important new science can be gained 
while, at the same time, assuring the safety of the community, the environment, 
and the worker. 
Dr. McKinney thanked Dr. Waitz for his comments. Dr. McKinney said the proposal 
to amend the NIH Guidelines for Research Involving Recombinant D1& Molecules 
will be forwarded to the RAC for consideration. The suggestions pertaining to 
the Physical Containment Recommendations for Large-Scale Uses of Organisms 
[SO] 
